DELFT, The Netherlands, Jan. 11, 2011 /PRNewswire/ -- DSM BioSolutions, Royal DSM’s microbial fermentation contract manufacturing business, and BiAqua B.V. (“BiAqua”), an innovator in delivering bio-based solutions for serious water contamination issues, today announced that they have entered into an agreement for strain development, process development and production of “BiAqua Ferritin” for BiAqua’s core technology to address bio-fouling and arsenic contamination in the water sector.
DSM has successfully started strain and process development of BiAqua Ferritin at its process development facility in Delft, The Netherlands and will shortly commence with scale-up and manufacturing of BiAqua Ferritin at its microbial fermentation biotech facility located in Capua, Italy. The BiAqua Ferritin will be used for BiAqua water contamination studies in collaboration with water companies and consumers worldwide to reduce bacterial and arsenic contamination. DSM’s Capua facility is uniquely equipped for the production of biologically active compounds produced via microbial fermentation and has extensive experience in both bacterial and fungal fermentation.
Nityen Lal, Managing Director of BiAqua, stated, “DSM has assembled a first class team to help us drastically optimize the cost of production on the basis of their expertise, proprietary tools and technology. This should enable BiAqua to offer an affordable bio-based solution to the market in the short term.”
Villaume Kal, Vice-President of DSM BioSolutions stated, “We are delighted to work with BiAqua, an innovative and progressive company developing bio-based solutions to worldwide water contamination issues. Our technology, operational excellence and outstanding regulatory compliance record allows us to serve this important customer and to develop and manufacture their Ferritin product.”
No financial terms will be disclosed.
BiAqua B.V.
BiAqua, a Dutch biotechnology company controlled by Icos Capital, is in the business of water security. Water security is the ability to access sufficient quantities of clean water to maintain minimal standards of food and goods production, sanitation and health. BiAqua is delivering bio-based solutions and related services for serious water contamination issues to water companies and consumers worldwide. The technology uses bio-based material, as opposed to chemical and other materials and solutions currently in the market. This technology is low cost, has broad usability, and works tremendously fast and reliably in the prevention of the growth of algae and bacteria. The technology also eliminates metals or carcinogens in the water including arsenic or bromide. For more information, please visit www.biaqua.nl
DSM BioSolutions Microbial Fermentation
DSM BioSolutions, part of the DSM Pharma cluster, offers a wide range of customer services ranging from process development to large scale production, all in the field of microbial fermentation. Expertise covers microbial strain construction and improvement, fermentation process development and product recovery and purification. DSM’s production infrastructure for fermentation and associated product recovery and purification is based in a multipurpose facility in Capua, Italy, which currently produces pharmaceutical intermediates and APIs (with the exception of beta-lactams), food/nutrition-related products and industrial products. In the Pharma area, production lines are available for cGMP manufacturing of small molecules and pharmaceutical proteins. The facilities comply with all relevant regulations and are regularly inspected by the respective authorities (e.g. EMA and FDA). More information www.dsmbiosolutions.com
DSM the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information www.dsm.com
For more information:
DSM: Villaume Kal Vice-President DSM BioSolutions Tel: +31 15 279 2173 Email villaume.kal@dsm.com Marco Oomen Sr. Director Business Development Europe & Japan Tel: +31 15 279 2251 Email marco.oomen@dsm.com DSM BioSolutions Alexander Fleminglaan 1 1613 AX Delft The Netherlands Telephone +31 15 2793504 Internet: www.dsmbiosolutions.com Email: info.dsmbiosolutions@dsm.com | BiAqua B.V.: Nityen Lal Managing Director Tel: +31 20 453 0777 Email n.lal@biaqua.nl | |
Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law.
SOURCE DSM BioSolutions
